Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Other financing activities (2019 - 2021)

GT Biopharma (GTBP) has disclosed Other financing activities for 6 consecutive years, with $4000.0 as the latest value for Q1 2021.

  • On a quarterly basis, Other financing activities fell 66.67% to $4000.0 in Q1 2021 year-over-year; TTM through Mar 2021 was $4000.0, a 66.67% decrease, with the full-year FY2014 number at -$16000.0, up 74.6% from a year prior.
  • Other financing activities was $4000.0 for Q1 2021 at GT Biopharma, up from -$12000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $12000.0 in Q1 2020 to a low of -$12000.0 in Q2 2020.
  • A 3-year average of $800.0 and a median of $4000.0 in 2019 define the central range for Other financing activities.
  • Biggest YoY gain for Other financing activities was 200.0% in 2020; the steepest drop was 200.0% in 2020.
  • GT Biopharma's Other financing activities stood at -$4000.0 in 2019, then crashed by 200.0% to -$12000.0 in 2020, then soared by 133.33% to $4000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Other financing activities are $4000.0 (Q1 2021), -$12000.0 (Q2 2020), and $12000.0 (Q1 2020).